儿童、青少年及青年非霍奇金淋巴瘤的长期生存者
本文综述儿童非霍奇金淋巴瘤(NHL)长期生存者的远期效应,包括慢性健康问题、功能与神经认知表现及健康相关生活质量。治疗已从「一刀切」转向基于组织学和风险分层的策略,多数新诊断儿童不再一线放疗,生存者群体异质性增加。
要点
- 儿童NHL总体生存率提高主要归因于国际治疗研究的发展与实施。
- 治疗范式已从「一刀切」转为基于组织学和风险分层的策略,多数新诊断儿童一线不再放疗。
- NHL生存者数量持续增加,远期并发症风险因治疗暴露不同而呈异质性。
核心结论
- 儿童NHL治疗已从「一刀切」转向组织学依赖和风险分层策略,多数新诊断儿童一线不再放疗,生存者群体异质性增加,需关注其远期并发症风险。
研究设计与样本
- 综述,总结儿童NHL长期生存者远期效应的现有文献,包括慢性健康问题、功能与神经认知表现及健康相关生活质量,并纳入从更广泛儿童癌症生存者群体外推的数据。
主要发现
- 总体生存率提高主要归因于国际治疗研究的发展与实施,这些研究使治疗从「一刀切」转为组织学依赖策略。
- 许多中心现采用风险分层方法,依据疾病侵袭性处方化疗累积剂量和强度。
- 认识到不使用放疗即可达到高治愈率,已使多数新诊断儿童一线治疗中不再使用放疗。
- NHL生存者群体异质性增加,其远期并发症风险因治疗暴露不同而多样。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Progress in overall survival rates for childhood non-Hodgkin lymphoma (NHL) can be largely attributed to effective development and conduct of a number of international treatment studies. Knowledge gained from these studies has shifted the treatment paradigm from a "one-size fits all" strategy to a histologically dependent approach. More specifically, many now adhere to a risk-stratified approach, prescribing cumulative doses and intensities of chemotherapeutic exposures based upon the aggressiveness of disease. Moreover, recognition that high cure rates could be achieved without the use of radiation has eliminated the use of this modality in frontline settings for the majority of newly diagnosed children. These changes have contributed to the emergence of a heterogeneous group of NHL survivors. As the number of NHL survivors continues to increase, providers will encounter a wide spectrum of individuals whose risk for long-term complications are accordingly diverse. The following review summarizes the existing literature surrounding late effects, such as chronic health conditions, functional and neurocognitive performance outcomes, and health-related quality of life, that are unique to NHL survivors, as well as those extrapolated from the broader childhood cancer survivor population.
引用
- Ehrhardt MJ, Hochberg J, Bjornard KL, et al. Long-term survivors of childhood, adolescent and young adult non-Hodgkin lymphoma. Br J Haematol. 2019. PMID: 30714126. doi:10.1111/bjh.15775
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。